Carnosic acid induces apoptosis through inactivation of Src/STAT3 signaling pathway in human renal carcinoma Caki cells

Oncology Reports

Volumn 35, Issue 5, 2016, Pages 2723-2732

  Park, Ji Eun ^a   Park, Byoungduck ^a   Chae, In Gyeong ^a   Kim, Do Hee ^b   Kundu, Juthika ^a   Kundu, Joydeb Kumar ^a   Chun, Kyung Soo ^a  

^a Keimyung University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Apoptosis; Carnosic acid; Reactive oxygen species; Renal cancer; Signal transducer and activator of transcription 3

Indexed keywords

ACETYLCYSTEINE; CARNOSIC ACID; CASPASE 3; CASPASE 7; CASPASE 9; CYCLINE; CYTOCHROME C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MDM2; PROTEIN P27; PROTEIN P53; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; SURVIVIN; ABIETANE DERIVATIVE; ANTINEOPLASTIC AGENT; STAT3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL CANCER CELL LINE; SIGNAL TRANSDUCTION; CARCINOMA, RENAL CELL; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; IC50; KIDNEY NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL SURVIVAL; DITERPENES, ABIETANE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; KIDNEY NEOPLASMS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR;

EID: 84964057229     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4642     Document Type: Article

References (55)

1. Motzer RJ, Bander NH and Nanus DM: Renal-cell carcinoma. N Engl J Med 335: 865-875, 1996.
2. Mulders P, Figlin R, deKernion JB, Wiltrout R, Linehan M, Parkinson D, deWolf W and Belldegrun A: Renal cell carcinoma: Recent progress and future directions. Cancer Res 57: 5189-5195, 1997.
3. Santoni M, De Tursi M, Felici A, Lo Re G, Ricotta R, Ruggeri EM, Sabbatini R, Santini D, Vaccaro V and Milella M: Management of metastatic renal cell carcinoma patients with poor-risk features: Current status and future perspectives. Expert Rev Anticancer Ther 13: 697-709, 2013.
4. Huang MT, Ho CT, Wang ZY, Ferraro T, Lou YR, Stauber K, Ma W, Georgiadis C, Laskin JD and Conney AH: Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res 54: 701-708, 1994.
5. Chen D and Dou QP: Tea polyphenols and their roles in cancer prevention and chemotherapy. Int J Mol Sci 9: 1196-1206, 2008.
6. Kerr JF, Wyllie AH and Currie AR: Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972.
7. Earnshaw WC, Martins LM and Kaufmann SH: Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68: 383-424, 1999.
8. Fulda S, Galluzzi L and Kroemer G: Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 9: 447-464, 2010.
9. Panaretakis T, Pokrovskaja K, Shoshan MC and Grandér D: Interferon-alpha-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax. Oncogene 22: 4543-4556, 2003.
10. Youle RJ and Strasser A: The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
11. Trachootham D, Lu W, Ogasawara MA, Nilsa RD and Huang P: Redox regulation of cell survival. Antioxid Redox Signal 10: 1343-1374, 2008.
12. Akgul C, Moulding DA and Edwards SW: Molecular control of neutrophil apoptosis. FEBS Lett 487: 318-322, 2001.
13. Kang YJ, Kim IY, Kim EH, Yoon MJ, Kim SU, Kwon TK and Choi KS: Paxilline enhances TRAIL-mediated apoptosis of glioma cells via modulation of c-FLIP, survivin and DR5. Exp Mol Med 43: 24-34, 2011.
14. Thorburn A: Death receptor-induced cell killing. Cell Signal 16: 139-144, 2004.
15. Ashkenazi A: Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 19: 325-331, 2008.
16. Neergheen VS, Bahorun T, Taylor EW, Jen LS and Aruoma OI: Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention. Toxicology 278: 229-241, 2010.
17. Huang S: Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: Clinical implications. Clin Cancer Res 13: 1362-1366, 2007.
18. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002.
19. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, et al: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10: 48-54, 2004.
20. Wang Y, Ma X, Yan S, Shen S, Zhu H, Gu Y, Wang H, Qin G and Yu Q: 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently crosslinking Janus kinases and induces apoptosis of human cancer cells. Cancer Res 69: 7302-7310, 2009.
21. Yu h and Jove R: The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4: 97-105, 2004.
22. Chen YF, Yang JS, Chang WS, Tsai SC, Peng SF and Zhou YR: Houttuynia cordata Thunb extract modulates G0/G1 arrest and Fas/CD95-mediated death receptor apoptotic cell death in human lung cancer A549 cells. J Biomed Sci 20: 18, 2013.
23. Kim HG, Hwang YP and Jeong HG: Kahweol blocks STAT3 phosphorylation and induces apoptosis in human lung adenocarcinoma A549 cells. Toxicol Lett 187: 28-34, 2009.
24. Jalali-Heravi M, Moazeni RS and Sereshti H: Analysis of Iranian rosemary essential oil: Application of gas chromatography-mass spectrometry combined with chemometrics. J Chromatogr A 1218: 2569-2576, 2011.
25. Ninomiya K, Matsuda H, Shimoda H, Nishida N, Kasajima N, Yoshino T, Morikawa T and Yoshikawa M: Carnosic acid, a new class of lipid absorption inhibitor from sage. Bioorg Med Chem Lett 14: 1943-1946, 2004.
26. Almela L, Sánchez-Muñoz B, Fernández-López JA, Roca MJ and Rabe V: Liquid chromatograpic-mass spectrometric analysis of phenolics and free radical scavenging activity of rosemary extract from different raw material. J Chromatogr A 1120: 221-229, 2006.
27. Ramírez P, García-Risco MR, Santoyo S, Señoráns FJ, Ibáñez E and Reglero G: Isolation of functional ingredients from rosemary by preparative-supercritical fluid chromatography (Prep-SFC). J Pharm Biomed Anal 41: 1606-1613, 2006.
28. López-García S, Castañeda-Sanchez JI, Jiménez-Arellanes A, Domínguez-López L, Castro-Mussot ME, Hernández-Sanchéz J and Luna-Herrera J: Macrophage activation by ursolic and oleanolic acids during mycobacterial infection. Molecules 20: 14348-14364, 2015.
29. Ortuño J, Serrano R and Bañón S: Antioxidant and antimicrobial effects of dietary supplementation with rosemary diterpenes (carnosic acid and carnosol) vs vitamin E on lamb meat packed under protective atmosphere. Meat Sci 110: 62-69, 2015.
30. Gaya M, Repetto V, Toneatto J, Anesini C, Piwien-Pilipuk G and Moreno S: Antiadipogenic effect of carnosic acid, a natural compound present in Rosmarinus officinalis, is exerted through the C/EBPs and PPARγ pathways at the onset of the differentiation program. Biochim Biophys Acta 1830: 3796-3806, 2013.
31. Ibarra A, Cases J, Roller M, Chiralt-Boix A, Coussaert A and Ripoll C: Carnosic acid-rich rosemary (Rosmarinus officinalis L.) leaf extract limits weight gain and improves cholesterol levels and glycaemia in mice on a high-fat diet. Br J Nutr 106: 1182-1189, 2011.
32. Tsai CW, Liu KL, Lin YR and Kuo WC: The mechanisms of carnosic acid attenuates tumor necrosis factor-α-mediated inflammation and insulin resistance in 3T3-L1 adipocytes. Mol Nutr Food Res 58: 654-664, 2014.
33. Wang T, Takikawa Y, Satoh T, Yoshioka Y, Kosaka K, Tatemichi Y and Suzuki K: Carnosic acid prevents obesity and hepatic steatosis in ob/ob mice. Hepatol Res 41: 87-92, 2011.
34. Xiang Q, Liu Z, Wang Y, Xiao H, Wu W, Xiao C and Liu X: Carnosic acid attenuates lipopolysaccharide-induced liver injury in rats via fortifying cellular antioxidant defense system. Food Chem Toxicol 53: 1-9, 2013.
35. Kundu JK, Shin YK, Kim SH and Surh YJ: Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis 27: 1465-1474, 2006.
36. Herr I and Debatin KM: Cellular stress response and apoptosis in cancer therapy. Blood 98: 2603-2614, 2001.
37. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
38. Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B and Bao JK: Programmed cell death pathways in cancer: A review of apoptosis, autophagy and programmed necrosis. Cell Prolif 45: 487-498, 2012.
39. Prasad S, Yadav VR, Kannappan R and Aggarwal BB: Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: Evidence for the role of reactive oxygen species and JNK. J Biol Chem 286: 5546-5557, 2011.
40. Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55: 178-194, 2005.
41. Wang X: The expanding role of mitochondria in apoptosis. Genes Dev 15: 2922-2933, 2001.
42. Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C and Kroemer G: Mechanisms of cytochrome c release from mitochondria. Cell Death Differ 13: 1423-1433, 2006.
43. Antonsson B and Martinou JC: The Bcl-2 protein family. Exp Cell Res 256: 50-57, 2000.
44. Han J, Goldstein LA, Gastman BR and Rabinowich H: Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 281: 10153-10163, 2006.
45. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, et al: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300, 1997.
46. Giaccia AJ and Kastan MB: The complexity of p53 modulation: Emerging patterns from divergent signals. Genes Dev 12: 2973-2983, 1998.
47. Shieh SY, Ikeda M, Taya Y and Prives C: DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334, 1997.
48. Gottlieb TM, Leal JF, Seger R, Taya Y and Oren M: Cross-talk between Akt, p53 and Mdm2: Possible implications for the regulation of apoptosis. Oncogene 21: 1299-1303, 2002.
49. Lotem J, Peled-Kamar M, Groner Y and Sachs L: Cellular oxidative stress and the control of apoptosis by wild-type p53, cytotoxic compounds, and cytokines. Proc Natl Acad Sci USA 93: 9166-9171, 1996.
50. Misra MK, Sarwat M, Bhakuni P, Tuteja R and Tuteja N: Oxidative stress and ischemic myocardial syndromes. Med Sci Monit 15: RA209-RA219, 2009.
51. Orrenius S, Gogvadze V and Zhivotovsky B: Mitochondrial oxidative stress: Implications for cell death. Annu Rev Pharmacol Toxicol 47: 143-183, 2007.
52. Kim DJ, Chan KS, Sano S and Digiovanni J: Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol Carcinog 46: 725-731, 2007.
53. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, Nagayasu T and Sekine I: Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 15: 1445-1451, 2006.
54. Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C and Lin J: STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res 71: 7226-7237, 2011.
55. Johnston PA and Grandis JR: STAT3 signaling: Anticancer strategies and challenges. Mol Interv 11: 18-26, 2011.